Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 1

Conditions

Melanoma 12Carcinoma, Non-Small-Cell Lung 12Neoplasm Metastasis 11Colorectal Neoplasms 9Triple Negative Breast Neoplasms 8Neoplasms 6Lymphoma 6Squamous Cell Carcinoma of Head and Neck 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Glioblastoma 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lung Neoplasms 2Liver Neoplasms 2Hematologic Diseases 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Advanced Solid Tumors 2Advanced Solid Tumor 2Adenocarcinoma 2von Hippel-Lindau Disease 1

Interventions

Temozolomide 107Radiotherapy 60Radiation 28Bevacizumab 19Magnetic Resonance Spectroscopy 16Nivolumab 15Surgical Procedures, Operative 12Irinotecan 11Cyclophosphamide 10Specimen Handling 9Chemotherapy, Adjuvant 9Radiotherapy, Intensity-Modulated 8Radiosurgery 8O(6)-benzylguanine 8Carmustine 8poly ICLC 7pembrolizumab 7motexafin gadolinium 7fludarabine 7Leukapheresis 7Flucytosine 7sargramostim 6Radiotherapy, Conformal 6Erlotinib Hydrochloride 6Lomustine 5Ipilimumab 5Imiquimod 5Imatinib Mesylate 5Hydroxyurea 5Granulocyte-Macrophage Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Glioblastoma × spartalizumab × Clear all
NCT03961971 2026-04-23

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Active not recruiting
16 enrolled
CNS

Glioblastoma

NCT02658981 2023-10-06

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
63 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT03707457 2020-07-02

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Terminated
3 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡